Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Newspaper Publication regarding dispatch of 22nd AGM Notice
Source: Bse
JHS Svendgaard Laboratories Limited (JHS)
Small CapPharma stocks · Small cap · NSE
JHS Svendgaard Laboratories Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
77BullishSMA20 +13.9% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 62
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
JHSD candles · FIT view+1.5%Latest close ₹9.31 on 2026-10-21
Bar
-5.4%
RSI
51
MACD hist
-0.12
52W pos
40%
2026-10-21O ₹9.84H ₹9.94L ₹9.00C ₹9.31Vol 81,833 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
JHSNifty PharmaNifty 500
- JHS
- +27.9%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +34.4 pp
Chart stats
21 Oct 2026- From 52W high
- -33.0%
- 52W range position
- 40%
- ATR (14)
- 8.6%
- Volume vs 20D
- 0.13x
- Avg traded value
- ₹0.7 Cr
- 20D price channel
- ₹8 - ₹13.7
₹13.9
₹6.3 - ₹13.9
₹0.8
Latest completed session
20-session average
109.3% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED12
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average32
Revenue +29.6% · PAT +2.8% YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence54
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 32/100margin compression · Rev +30% YoY · PAT +3% YoY
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹30.4 Cr | +29.6% | -7.1% |
| EBITDA | ₹2.1 Cr | +24.7% | +226.2% |
| Operating margin | 6.8% | -27 bps | +1183 bps |
| PAT | ₹1.1 Cr | +2.8% | NDF |
| PAT margin | 3.6% | -93 bps | +1451 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 0.53
- EV/EBITDA
- 10.70
- Market Cap
- 92.00Cr
Profitability
- ROE
- -1.17%
- ROCE
- -0.84%
- ROA
- -0.93%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 5.87%
- EPS 5Y
- -17.00%
- Revenue 3Y
- 6.00%
- EPS 3Y
- -22.00%
Balance Sheet
- Debt/Equity
- 0.09
- Interest Coverage
- 3.00×
- Altman Z
- 2.72
- Book Value
- 20.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 3/5
- OCF
- -3.00 Cr
- EPS TTM
- -0.22
Shareholding
- Promoter Hold
- 33.85%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 56%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 30.4-7.1% vs prev
Net Profit
₹ CrLatest: 1.1+130.5% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bullish setupTrend is constructive — long-term uptrend intact. RSI 51.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- Recent golden cross (SMA50 crossed above SMA200).
- SMA20 rising (~12.2% over last month) — short-term momentum positive.
- RSI(14) at 51 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 33% off 52W high · 49% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 12 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 12 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation7/30
Growth2/25
Quality0/20
Balance Sheet8/15
Cash Flow2/10
Piotroski
3/9 (+1)
Penalties
-8
Raw sum
12
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
12/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 8/15 to the score.
- Valuation contributes 7/30 to the score.
- Cash flow contributes 2/10 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Growth is weaker at 2/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
0.5
EV/EBITDA
10.7
ROE
-1.2%
ROCE
-0.8%
FCF Yield
—
Debt/Equity
0.1
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
12
Previous: 12
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
12
12
12
12
12
12
12
12
12
12
12
12
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
2.7
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
BALAXI
Small
BALAXI PHARMACEUTICALS LIMITED
Pharmaceuticals
match 164
9
51.7
0.6%
-5589%
OVERVALUED
ALPA
Small
Alpa Laboratories Limited
Pharmaceuticals
match 163
32
30.6
8.4%
+40%
WATCHLIST
ONYX
SME
Onyx Biotec Ltd.
Pharmaceuticals
match 159
15
—
-0.4%
—
OVERVALUED
BALPHARMA
Small
Bal Pharma Limited
Pharmaceuticals
match 159
23
23.6
7.9%
-44%
OVERVALUED
SOTAC
SME
Sotac Pharmaceuticals Ltd.
Pharmaceuticals
match 158
55
17.5
10.1%
+62%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
JHS Svendgaard Laboratories Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
54Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 13th percentile of the scored universe and 9th percentile within Pharma. Main check: financial discipline is weak at 22/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
32 docs text-extracted · 10 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
13th percentile
overall median 67 · Pharma: 9th pctile, median 70 · Small: 15th pctile, median 66
Evidence depth
Financial-only
32 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
40
weak · profit to cash conversion
Balance sheet
80
strong · leverage and solvency
Discipline
22
weak · capital discipline
Results
50
watch · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.09.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Operating cash flow is negative at ₹-3 Cr.
- ▸ROCE is low at -0.8%.
- ▸ROE is low at -1.1%.
- ▸ROCE trend is -2.8%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching JHS Svendgaard Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Aug - JHS Svendgaard Laboratories Limited has informed about the publication of Newspaper Advertisement regarding the details of Annual General Meeting.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.